# Atia Vision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atia-vision

- Industry: Healthcare Specialists
- Headquarters: Campbell, US
- Website: www.atiavision.com
- Total disclosed funding: $53M
- Latest round: Series E (Jul 29, 2022)
- Investors on record: 6

## About

Atia Vision, Inc. specializes in innovative intraocular lenses designed to improve vision for cataract patients, featuring advanced technology to enhance visual clarity and reduce disturbances associated with traditional options.Atia Vision, Inc. was founded in 2012 in Campbell, US, focusing on developing intraocular lens solutions. The company has completed 7 deals, with the most recent funding round occurring on July 29, 2022. Atia Vision raised USD 28.65 mn during its Series E funding led by Cormorant Asset Management, alongside participation from AMED Ventures, Picard Angst, and The Capital Partnership (U.K.) Limited. The company is founded by Claudio Argento, who has a history of entrepreneurship in the medical device sector, and is currently led by CEO Mariam Maghribi.Atia Vision, Inc. develops innovative intraocular lenses (IOLs) aimed at enhancing vision for cataract patients. The flagship product, the OmniVu™ Lens System, features a dual-optic design with a shape-changing, fluid-filled base and fixed power front optic, designed to restore a full range of functional vision while minimizing common disturbances like halos and glare. The OmniVu™ Lens System will be utilized in cataract surgeries and is progressing towards clinical trials in the United States.Atia Vision’s revenue model is based on selling its proprietary intraocular lenses, particularly the OmniVu™ Lens System, directly to ophthalmic surgeons and healthcare facilities involved in cataract surgeries. This model facilitates a direct relationship with medical institutions, where the lenses are integrated into surgical procedures for patients undergoing cataract removal and lens replacement. The product aims for extensive market penetration in regions with high cataract surgery rates, although specific pricing plans remain undisclosed.Following the Series E funding round in July 2022, Atia Vision, Inc. plans to utilize the USD 28.65 mn raised to enhance its clinical program and expand its manufacturing capabilities. The company aims to introduce new products and expand into new geographic markets. Specific plans for market expansion have not been detailed, but the focus will likely include regions with significant cataract surgery demand. Atia Vision intends to strengthen its vision team to support these growth initiatives.

## Funding rounds

- Series E, Jul 29, 2022, $29M — Cormorant Asset Management, The Capital Partnership (U.K.) Limited, AMED Ventures, Picard Angst
- Series D, May 19, 2020 — Cormorant Asset Management, ShangBay Capital, The Capital Partnership (U.K.) Limited, AMED Ventures
- Series D, Apr 26, 2019, $12M — Cormorant Asset Management, ShangBay Capital, The Capital Partnership (U.K.) Limited, AMED Ventures
- Series C, Dec 10, 2018, $10M — Cormorant Asset Management, Delos Capital Partners, The Capital Partnership (U.K.) Limited
- Series B, Apr 29, 2015, $3M — Delos Capital Partners

## Investors

- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C, Series D, Series E
- The Capital Partnership (U.K.) Limited — Series C, Series D, Series E
- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series D
- AMED Ventures (https://capitalatlas.ai/funds/amed-ventures) — Series D, Series E
- Picard Angst (https://capitalatlas.ai/funds/picard-angst) — Series E